VU6067416

Chemical compound

File:VU6067416.png

Chemical structure of VU6067416

VU6067416 is a chemical compound that has been studied for its potential effects on the central nervous system. It is primarily known as a selective positive allosteric modulator of the metabotropic glutamate receptor 4 (mGluR4), which is a subtype of the metabotropic glutamate receptor family. These receptors are involved in modulating glutamate neurotransmission, which plays a crucial role in various neurological processes.

Chemical Properties

VU6067416 is characterized by its specific chemical structure, which allows it to interact selectively with mGluR4. The compound's molecular formula is C₂₀H₁₈ClN₃O₂, and it has a molecular weight of 367.83 g/mol. The presence of a chlorine atom and a complex aromatic structure contributes to its binding affinity and selectivity.

Mechanism of Action

VU6067416 functions as a positive allosteric modulator (PAM) of mGluR4. Unlike agonists that directly activate receptors, PAMs enhance the receptor's response to its natural ligand, in this case, glutamate. By modulating mGluR4, VU6067416 can influence synaptic transmission and neuronal excitability, potentially offering therapeutic benefits in conditions where glutamate signaling is dysregulated.

Potential Therapeutic Applications

Research into VU6067416 has primarily focused on its potential use in treating Parkinson's disease and other neurodegenerative disorders. The modulation of mGluR4 is thought to provide neuroprotective effects and improve motor function by reducing excessive glutamatergic activity, which is often implicated in the pathophysiology of these diseases.

Pharmacokinetics

The pharmacokinetic profile of VU6067416 includes its absorption, distribution, metabolism, and excretion characteristics. Studies have shown that it has a favorable bioavailability and can cross the blood-brain barrier, which is essential for its action on central nervous system targets. The compound is metabolized primarily in the liver and excreted via the kidneys.

Research and Development

VU6067416 is still under investigation, with ongoing studies aimed at understanding its full pharmacological profile and therapeutic potential. Preclinical trials have demonstrated promising results, but further research is needed to evaluate its safety and efficacy in humans.

Related Pages

• Metabotropic glutamate receptor
• Glutamate (neurotransmitter)
• Parkinson's disease
• Neurodegenerative disorder